![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to prepare commercial readiness for the potential market launch of the company’s phase III lead candidate, ITM-11 (177Lu-edotreotide) for the treatment of GEP-NETs.
Lead Product(s): Lutetium-177-edotreotide
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Temasek
Deal Size: $204.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 06, 2024
Details:
ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment, which is currently being evaluated for the treatment of glioblastoma.
Lead Product(s): Lu-177 labeled 6A10-Fab-fragments
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Helmholtz Zentrum München
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
Through collaboration, ITM will supply its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu) for Alpha-9's Lutetium-based candidates for the treatment of cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alpha-9 Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 30, 2024
Details:
Under the agreement, Merck will supply ITM with its first-in-class folate precursors for radiolabeling, which ITM will use to advance the clinical and potential future commercial development of its folate receptor-targeting radiopharmaceutical pipeline, including ITM-52.
Lead Product(s): ITM-52
Therapeutic Area: Oncology Product Name: ITM-52
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2023
Details:
The expanded agreement broadens the supply of ITM’s n.c.a. 177Lu to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline, including 177Lu-PNT2002 for prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2023
Details:
The net financing will support the development of ITM’s broad Targeted Radionuclide Therapies oncology pipeline and enhance phase III clinical development for its lead pipeline candidate, ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): n.c.a. 177Lu-Edotreotide,Everolimus
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Temasek
Deal Size: $272.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 05, 2023
Details:
Under the agreement, the partners will combine their respective technologies and expertise in the production of terbium-161 including clinical and commercial use in Targeted Radionuclide Therapy (TRT) for the treatment of cancer.
Lead Product(s): Terbium-161
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Paul Scherrer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 27, 2023
Details:
ITM-31 targets a specific protein (antigen) called CA XII, which is highly expressed on the cell surface of glioblastoma cells and destroys them while sparing the healthy tissues. It comprises a CA XII antibody Fab fragment coupled with the radioisotope 177Lu.
Lead Product(s): ITM-31
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Hospital Muenster
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
ITM-11 consists of two components: the medical radioisotope non-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors.
Lead Product(s): Lutetium-177-edotreotide
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Under the terms of the license agreement, ITM will hold exclusive rights to the compound ITM-31 as well as the rights to related patents and know-how for the manufacturing and use of ITM-31.
Lead Product(s): ITM-31
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Helmholtz Zentrum München
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 19, 2022